Search results for " Liver neoplasm"

showing 10 items of 78 documents

The role of PNI to predict survival in advanced hepatocellular carcinoma treated with Sorafenib

2020

Background and aims The present study aims to investigate the role of the prognostic nutritional index (PNI) on survival in patients with advanced hepatocellular carcinoma (HCC) treated with sorafenib. Methods This multicentric study included a training cohort of 194 HCC patients and three external validation cohorts of 129, 76 and 265 HCC patients treated with Sorafenib, respectively. The PNI was calculated as follows: 10 × serum albumin (g/dL) + 0.005 × total lymphocyte count (per mm3). Univariate and multivariate analyses were performed to investigate the association between the covariates and the overall survival (OS). Results A PNI cut-off value of 31.3 was established using the ROC an…

RNA virusesMaleEtiologyCancer TreatmentHepacivirusKaplan-Meier EstimateBiochemistryCohort StudiesWhite Blood CellsMathematical and Statistical TechniquesRetrospective StudieAnimal CellsAdult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Cohort Studies; Female; Humans; Italy; Kaplan-Meier Estimate; Liver Neoplasms; Lymphocyte Count; Male; Middle Aged; Prognosis; Retrospective Studies; Serum Albumin; Sorafenib; Nutrition AssessmentMedicine and Health Sciences80 and overLymphocytesPathology and laboratory medicineAged 80 and overHepatitis C virusLiver DiseasesStatisticsQLiver NeoplasmsRMedical microbiologyMiddle AgedSorafenibPrognosisOncologyItalyLiver NeoplasmPhysical SciencesVirusesMedicineFemalePathogensCellular TypesHumanResearch ArticleAdultHepatitis B virusCarcinoma HepatocellularImmune CellsScienceImmunologyAntineoplastic AgentsGastroenterology and HepatologySerum Albumin ...Research and Analysis MethodsCarcinomasMicrobiologyAlbuminsGastrointestinal TumorsHumansLymphocyte CountStatistical MethodsSerum AlbuminAgedRetrospective StudiesBlood CellsAdult Aged 80 and over Antineoplastic Agents Carcinoma Hepatocellular Cohort Studies Female Humans Italy Kaplan-Meier Estimate Liver Neoplasms Lymphocyte Count Male Middle Aged Prognosis Retrospective Studies Serum Albumin Sorafenib Nutrition AssessmentBiology and life sciencesFlavivirusesCarcinomaViral pathogensOrganismsCancers and NeoplasmsProteinsHepatocellularHepatocellular CarcinomaCell Biologyprognostic nutritional index (PNI) hepatocellular carcinoma (HCC) sorafenib. survival mRECISTHepatitis virusesMicrobial pathogensNutrition AssessmentMultivariate AnalysisCohort StudieMathematics
researchProduct

Evaluation of washout using subtraction MRI for the diagnosis of hepatocellular carcinoma in cirrhotic patients with spontaneously T1-hyperintense no…

2023

Purpose: The purpose of this study was to assess the value of subtraction imaging on post-arterial phase images (i.e., portal venous, delayed/transitional and hepatobiliary phases) for the non-invasive diagnosis of hepatocellular carcinoma (HCC) in spontaneously hyperintense nodules on T1-weighted imaging in patients with cirrhosis. Materials and methods: Forty-five patients with a total 55 hepatic nodules that were spontaneously hyperintense on T1-weighted images were initially retrieved. All patients underwent MRI examination of the liver using extracellular agent. Each nodule was assessed for sensitivity and specificity using LI-RADS (Liver Imaging Reporting and Data System) during two r…

Radiological and Ultrasound TechnologyDiagnostic imaging Subtraction imaging Hepatocellular carcinoma Magnetic resonance imaging Liver neoplasmRadiology Nuclear Medicine and imagingGeneral MedicineDiagnostic and Interventional Imaging
researchProduct

ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents

2016

Objectives: To develop a consensus and provide updated recommendations on liver MR imaging and the clinical use of liver-specific contrast agents. Methods: The European Society of Gastrointestinal and Abdominal Radiology (ESGAR) formed a multinational European panel of experts, selected on the basis of a literature review and their leadership in the field of liver MR imaging. A modified Delphi process was adopted to draft a list of statements. Descriptive and Cronbach’s statistics were used to rate levels of agreement and internal reliability of the consensus. Results: Three Delphi rounds were conducted and 76 statements composed on MR technique (n = 17), clinical application of liver-speci…

Radiology Nuclear Medicine and ImagingDelphi TechniqueStatement (logic)030218 nuclear medicine & medical imaging0302 clinical medicineNuclear Medicine and ImagingDelphi techniqueAumento da ImagemDiagnosisMedicineImagerie médicale radiologie tomographiehealth care economics and organizationsNeuroradiologySettore MED/36 - DIAGNOSTICA PER IMMAGINI E RADIOTERAPIAmedicine.diagnostic_testLiver CellLiver DiseaseContrast mediaLiver DiseasesLiver NeoplasmsBile DuctInterventional radiologyGeneral MedicineBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Radiology Nuclear Medicine and ImagingMagnetic Resonance ImagingLiverBiliary tractRadiology Nuclear Medicine and imagingLiver Neoplasm030220 oncology & carcinogenesisRadiologyRadiologyHumanRadiography AbdominalAdenomamedicine.medical_specialtyConsensuseducationReproducibility of ResultConsensuBiliary tract; Contrast media; Delphi technique; Liver; Magnetic resonance imaging; Adenoma Liver Cell; Bile Ducts; Consensus; Delphi Technique; Diagnosis Differential; Humans; Liver Diseases; Liver Neoplasms; Magnetic Resonance Imaging; Radiography Abdominal; Reproducibility of Results; Contrast MediaAdenoma Liver CellDiagnosis Differential03 medical and health sciencesMagnetic resonance imagingHumansAbdominalRessonância MagnéticaMeios de ContrasteComputer. Automationbusiness.industryReproducibility of ResultsMagnetic resonance imagingMr imagingClinical trialRadiographyDifferentialBiliary tractBile DuctsDifferential diagnosisbusiness
researchProduct

Years of life that could be saved from prevention of hepatocellular carcinoma

2016

Summary Background Hepatocellular carcinoma (HCC) causes premature death and loss of life expectancy worldwide. Its primary and secondary prevention can result in a significant number of years of life saved. Aim To assess how many years of life are lost after HCC diagnosis. Methods Data from 5346 patients with first HCC diagnosis were used to estimate lifespan and number of years of life lost after tumour onset, using a semi-parametric extrapolation having as reference an age-, sex- and year-of-onset-matched population derived from national life tables. Results Between 1986 and 2014, HCC lead to an average of 11.5 years-of-life lost for each patient. The youngest age-quartile group (18–61 y…

RegistrieMalePediatricsDatabases FactualHepatocellular carcinoma0302 clinical medicineprevention80 and overSecondary PreventionPharmacology (medical)Prospective StudiesRegistriesYoung adultProspective cohort studySecondary preventionAged 80 and overeducation.field_of_studyLiver NeoplasmsGastroenterologyDisease ManagementMiddle AgedPrimary PreventiondiagnosiItalyLiver Neoplasm030220 oncology & carcinogenesisHepatocellular carcinoma030211 gastroenterology & hepatologyFemaleHumanAdultmedicine.medical_specialtyCarcinoma HepatocellularAdolescentPopulationlife expentancyMilan criteria03 medical and health sciencesDatabasesYoung AdultLife ExpectancymedicineHumansAdolescent; Adult; Aged; Aged 80 and over; Carcinoma Hepatocellular; Databases Factual; Disease Management; Female; Humans; Italy; Life Expectancy; Liver Neoplasms; Male; Middle Aged; Primary Prevention; Prospective Studies; Registries; Secondary Prevention; Young Adult; Pharmacology (medical)educationFactualAgedHepatologybusiness.industryCarcinomaSettore MED/09 - MEDICINA INTERNAHepatocellularmedicine.diseaseSurgeryProspective StudieYears of potential life lostLife expectancybusiness
researchProduct

Benign liver lesions 2022: Guideline for clinical practice of Associazione Italiana Studio del Fegato (AISF), Società Italiana di Radiologia Medica e…

2022

Benign liver lesions are increasingly diagnosed in daily clinical practice due to the growing use of imaging techniques for the study of the abdomen in patients who have non-specific symptoms and do not have an increased risk of hepatic malignancy. They include simple or parasitic cysts and solid benign tumors which differ widely in terms of prevalence, clinical relevance, symptoms and natural history and often lead to significant clinical problems relating to diagnosis and clinical management. Following the need to have updated guidelines on the management of benign focal liver lesions, the Scientific Societies mainly involved in their management have promoted the drafting of a new dedicat…

Settore MED/09 - Medicina InternaComplicated hepatic cystHepatologyComplicated hepatic cyst Focal liver lesion Parasitic hepatic cyst Polycystic liver disease Simple hepatic cyst HumansAbdomen Italy Digestive System Diseases Cysts Liver NeoplasmsDigestive System DiseasesSettore MED/18 - CHIRURGIA GENERALELiver NeoplasmsFocal liver lesion Focal nodular hyperplasia Hepatic hemangioma Hepatocellular adenomaGastroenterologyHepatic hemangiomaSimple hepatic cystHepatocellular adenomaPolycystic liver diseaseItalyAbdomenFocal liver lesionFocal nodular hyperplasiaHumansParasitic hepatic cystDigestive and Liver Disease
researchProduct

The calm before the storm: a report from the International Liver Cancer Association Congress 2015 – part 1

2016

International Liver Cancer Association Congress 2015, Paris, France, 4–6 September 2015 Since its creation 9 years ago, in 2007, the International Liver Cancer Association has focused on the multidisciplinary approach to liver cancer due to advances in hepatology science and care worldwide. In its 2015 annual conference, held on 4–6 September in Paris, France, the most recent progresses in the basic biology, management and treatment of liver cancer have been presented. This report, divided into two parts, introduces and critically reviews some of the most intriguing topics discussed at the meeting.

SorafenibCancer Researchmedicine.medical_specialtysurvivalliver cancer03 medical and health sciences0302 clinical medicineInternal medicinestaging systemmedicineHumansHCCDisease management (health)Staging systembusiness.industryCarcinomaLiver NeoplasmsDisease ManagementHCC; immunotherapy; liver cancer; prognosis; sorafenib; staging system; survival; trial design; Carcinoma Hepatocellular; Disease Management; Humans; Liver Neoplasms; Oncology; Cancer ResearchHepatocellularGeneral MedicineHepatologymedicine.diseaseOncology030220 oncology & carcinogenesisFamily medicinetrial designsorafenib030211 gastroenterology & hepatologyimmunotherapyprognosisLiver cancerbusinessmedicine.drugFuture Oncology
researchProduct

Outcomes of hepatocellular carcinoma patients treated with sorafenib: a meta-analysis of Phase III trials

2019

Aim: To benchmark overall survival (OS) and time to radiological progression (TTP) of patients enrolled in randomized controlled trials (RCTs) assessing sorafenib in advanced hepatocellular carcinoma using individual participant survival data, and to meta-analyze prognostic factors for OS and TTP. Methods: RCTs were identified through literature search until December 2018. Individual participant survival was reconstructed with an algorithm from published Kaplan–Meier curves. Results: Ten RCTs were included. Median OS was 10.0 months (95% CI: 9.6–10.5), and median TTP was 4.1 months (95% CI: 3.8–4.3). Multivariable analyses showed HCV positivity, absence of macrovascular invasion and extra-…

SorafenibOncologyCancer Researchmedicine.medical_specialtyCarcinoma HepatocellularPhase iii trialsAntineoplastic AgentsDiseasesurvivaltime to progressionSystemic therapysystemic therapylaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemeta-regressionmedicineHumansClinical TrialsMeta-regressionbusiness.industryCarcinomaLiver NeoplasmsHepatocellularhepatocellular carcinomaGeneral MedicineSorafenibmedicine.diseasePhase III as TopicSurvival RateTreatment Outcomehepatocellular carcinoma; meta-regression; sorafenib; survival; systemic therapy; time to progression; Antineoplastic Agents; Carcinoma Hepatocellular; Clinical Trials Phase III as Topic; Humans; Liver Neoplasms; Sorafenib; Survival Rate; Treatment OutcomeClinical Trials Phase III as TopicOncology030220 oncology & carcinogenesisHepatocellular carcinomaMeta-analysissorafenib030211 gastroenterology & hepatologybusinessmedicine.drug
researchProduct

The stable repression of mesenchymal program is required for hepatocyte identity: A novel role for hepatocyte nuclear factor 4α

2011

The concept that cellular terminal differentiation is stably maintained once development is complete has been questioned by numerous observations showing that differentiated epithelium may undergo an epithelial-to-mesenchymal transition (EMT) program. EMT and the reverse process, mesenchymal-to-epithelial transition (MET), are typical events of development, tissue repair, and tumor progression. In this study, we aimed to clarify the molecular mechanisms underlying these phenotypic conversions in hepatocytes. Hepatocyte nuclear factor 4α (HNF4α) was overexpressed in different hepatocyte cell lines and the resulting gene expression profile was determined by real-time quantitative polymerase…

Transcription FactorCellular differentiationMESH: Mice KnockoutMESH: HepatocytesMesodermMice0302 clinical medicineMESH: Liver NeoplasmsMESH: AnimalsHepatocyteHepatocyte Nuclear Factor 1-alphaMESH: Carcinoma HepatocellularRegulator geneHepatocyte differentiationMice KnockoutMESH: Mesoderm0303 health sciencesLiver NeoplasmsCell DifferentiationMESH: Transcription FactorsCell biologyHepatocyte nuclear factorsPhenotypeMESH: Models AnimalHepatocyte Nuclear Factor 4MESH: Epithelial CellsLiver Neoplasm030220 oncology & carcinogenesisModels AnimalMESH: Hepatocyte Nuclear Factor 4HumanMESH: Cell DifferentiationMESH: Cell Line TumorCarcinoma Hepatocellular[SDV.BC]Life Sciences [q-bio]/Cellular BiologyBiologyMESH: PhenotypeArticle03 medical and health scienceshepatocyte; mesenchymal program; SnailCell Line TumorAnimalsHumansMESH: Hepatocyte Nuclear Factor 1-alphaMESH: MiceTranscription factorAnimals; Carcinoma Hepatocellular; Cell Differentiation; Cell Line Tumor; Epithelial Cells; Hepatocyte Nuclear Factor 1-alpha; Hepatocyte Nuclear Factor 4; Hepatocytes; Humans; Liver Neoplasms; Mesoderm; Mice; Mice Knockout; Models Animal; Phenotype; Snail Family Transcription Factors; Transcription Factors; Hepatology030304 developmental biologyEpithelial CellMESH: HumansHepatologyAnimalMesenchymal stem cellEpithelial CellsSnail Family Transcription FactorMolecular biologyHepatocyte nuclear factor 4HepatocytesSnail Family Transcription FactorsChromatin immunoprecipitationTranscription Factors
researchProduct

TGFβ-induced EMT requires focal adhesion kinase (FAK) signaling

2007

The epithelial-to-mesenchymal transition (EMT) is a crucial process, occurring both during development and tumor progression, by which an epithelial cell undergoes a conversion to a mesenchymal phenotype, dissociates from initial contacts and migrates to secondary sites. We recently reported that in hepatocytes the multifunctional cytokine TGFβ induces a full EMT characterized by (i) Snail induction, (ii) E-cadherin delocalization and down-regulation, (iii) down-regulation of the hepatocyte transcriptional factor HNF4α and (iv) up-regulation of mesenchymal and invasiveness markers. In particular, we showed that Snail directly causes the transcriptional down-regulation of E-cadherin and HN…

Transcriptional ActivationTGFβFAK; MT; Src; TGFβ; Animals; Biomarkers Tumor; Cadherins; Cell Line; Cell Transformation Neoplastic; Enzyme Activation; Epithelial Cells; Focal Adhesion Protein-Tyrosine Kinases; Hepatocytes; Liver Neoplasms; Mesoderm; Mice; Neoplasm Invasiveness; Signal Transduction; Transcriptional Activation; Transforming Growth Factor beta; Up-Regulation; src-Family Kinases; Cell BiologyCell LineMesodermFocal adhesionMiceTransforming Growth Factor betaBiomarkers TumorAnimalsHepatocyteNeoplasm InvasivenessNeoplasm InvasiveneEpithelial CellFocal Adhesion Protein-Tyrosine KinaseFAKbiologyAnimalCadherinLiver NeoplasmsMesenchymal stem cellEpithelial CellsCell BiologyTransforming growth factor betaTgf beta; fak; srcCadherinsUp-RegulationCell biologyEnzyme ActivationCell Transformation Neoplasticsrc-Family KinasesHepatocyte nuclear factor 4Liver NeoplasmTumor progressionMTFocal Adhesion Protein-Tyrosine KinasesCadherinHepatocytesCancer researchbiology.proteinsrc-Family KinaseSignal transductionSrcSignal TransductionProto-oncogene tyrosine-protein kinase SrcExperimental Cell Research
researchProduct

Waiting-time and quality of care deserved to patients with early stage hepatocellular carcinoma undergoing RFA treatment

2017

Waiting timemedicine.medical_specialtyCarcinoma HepatocellularSettore MED/09 - Medicina InternaHepatologybusiness.industryLiver NeoplasmsSpecialties of internal medicineGeneral Medicinemedicine.diseaseSurgeryRC581-951Liver NeoplasmHepatocellular carcinomamedicineCatheter AblationHumansHepatectomyCatheter Ablation; Hepatectomy; Humans; Quality of Health Care; Carcinoma Hepatocellular; Liver Neoplasms; HepatologyStage (cooking)Quality of carebusinessHumanQuality of Health Care
researchProduct